Charter Communications Inc vs Zimmer Biomet Holdings Inc — how do they compare? Charter Communications Inc trades at $150.4 (market cap $18.81B), while Zimmer Biomet Holdings Inc trades at $95.43 (market cap $18.55B). The key difference: Charter Communications Inc and Zimmer Biomet Holdings Inc are close in size by market cap, and Zimmer Biomet Holdings Inc pays a 0.99% dividend while Charter Communications Inc pays none. Which is the better fit depends on your goals.
| CHTR | ZBH | |
|---|---|---|
Market Cap | $18.81B | $18.55B |
Sector | Media | Health |
52-Week High | $282.74 | $107.71 |
52-Week Low | $123.31 | $79.58 |
Enterprise Value | $115.01B | $25.61B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
Charter Communications (CHTR) trades at $153.29, up 0.47% today, near its pivot point of $152. The stock shows mixed technical signals with a bullish moving average trend but bearish oscillators. Fundamentally, it trades at low valuation multiples (P/E 4.1, P/S 0.37) with solid profitability (ROE 29.7%, net margin 9.05%), though Q1 2026 earnings missed expectations. Recent news highlights debt refinancing activities and competitive pressures in broadband.
Outlook: CHTR presents a value opportunity with deep discount to historical multiples, supported by strong cash flow and buybacks, but faces headwinds from subscriber losses and high debt load. Risks include fiber competition and revenue declines, while analyst consensus leans bullish with a $166.18 price target.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Trailing returns across standard periods
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →